Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
NO
INDIRECT
Ociperlimab binds TIGIT on target cells and its IgG1 Fc engages CD16A on NK cells to trigger ADCC/ADCP against TIGIT+ cells; CD16A-expressing cells act as effectors, not targets.
Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
NO
INDIRECT
Ociperlimab binds TIGIT; its IgG1 Fc engages Fcγ receptors (including CD32A) on myeloid/NK cells to mediate ADCC/ADCP of TIGIT-expressing cells. CD32A+ cells act as effectors and are not targeted or killed.
Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
NO
INDIRECT
The antibody binds TIGIT on target cells and uses its IgG1 Fc to engage CD64 on effector myeloid cells, driving ADCC/ADCP against TIGIT+ cells. CD64+ cells serve as effectors and are not directly killed.
Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
NO
INDIRECT
Ociperlimab targets TIGIT, not FcγRIIB (CD32B). Its IgG1 Fc can mediate ADCC/ADCP against TIGIT-expressing cells, but CD32B+ cells are not bound/opsonized by the antibody and are not directly killed.
Investigational intravenous bispecific antibody immunotherapy (immune-cell engager) that binds Claudin-6 on tumor cells and an immune effector cell receptor to trigger immune-mediated killing of CLDN6-positive cancers.
ASP1893 is an investigational bispecific antibody that binds Claudin‑6 on tumor cells and a receptor on T cells (e.g., CD3), bringing T cells into close proximity to CLDN6‑positive tumor cells to trigger T‑cell activation and cytotoxic killing.
YES
DIRECT
Bispecific antibody engages CD3 on T cells and CLDN6 on tumor cells, forming an immune synapse that activates T cells to kill CLDN6+ cells via perforin/granzyme–mediated apoptosis.